

DSM Press Release

DSM Nutritional Products, Communications
P.O. Box 2676, 4002 Basel, Switzerland
Telephone +41 (0)61 815 83 54, Fax +41 (0)61 815 88 90
Internet: www.dsmnutritionalproducts.com



Kaiseraugst (CH), 17th December 2009

DSM Nutritional Products announces first human data on resVida[®] trans-resveratrol which demonstrates cardiovascular health benefits

DSM Nutritional Products announced data from two analyses of the first human study of resVida[®] trans-resveratrol presented at the 4th International Conference on Polyphenols and Health (ICPH) in Yorkshire, England, Dec. 7-10, 2009 and the Nutrition Society of Australia (NSA) and Nutrition Society of New Zealand (NSNZ) Joint Annual Scientific Meeting in Newcastle, NSW, Australia, Dec. 8-11, 2009. The cardiovascular health benefits of resVida[®] shown by these data are among the first to exhibit health benefits in humans by any trans-resveratrol dietary ingredient.

In a double blind placebo controlled trial, human subjects were given orally three different doses of resVida[®] trans-resveratrol (30, 90 and 270 mg) which were all well absorbed into the blood stream in a dose dependent manner. The target of this study was to measure the influence of resveratrol on the reactivity of blood vessels which is a bio-marker linked to the functioning of the cardiovascular system. In the study, blood vessel reactivity was measured by blocking blood flow in the forearm for several minutes and measuring the degree of dilation of the brachial artery after release of the blocking cuff. The study showed that resVida[®] was readily absorbed and significantly improved blood vessel function compared to placebo at all three doses, as assessed by acute flow-mediated dilation (FMD). FMD is the ability of the main artery in the upper arm (the brachial artery) to expand as blood passes through. FMD is a recognized indicator of blood vessel function and sustained improvements in FMD are associated with a healthy cardiovascular system. The diameter of the artery increased by 62% at the 30 mg dose when compared to placebo, rising to 91% improvement at the 270 mg dose.^{1,2}

About Resveratrol

Resveratrol is a powerful antioxidant nutrient that helps protect the body from the aging effects of free radicals and oxidative stress, which can lead to premature aging of cells. Scientific studies have shown that concentrated resveratrol activates the human genes responsible for longevity, survival and cardiovascular health, as well exerts promising effects against certain diseases. Resveratrol mimics the effect of calorie restriction^{3,4,5}, the only scientific intervention proven to slow aging and extend life.⁶

About resVida[®] Trans-resveratrol

resVida[®] is a 99 percent pure form of trans-resveratrol with self-affirmed GRAS (Generally Recognized As Safe) status by a nationally recognized, independent panel of experts in the US. resVida[®] is produced according to Food GMPs and is free from pesticide and herbicide residues. resVida[®] is the only trans-resveratrol with a comprehensive safety package and demonstrated absorption, or bioavailability, in humans, which has been proven in multiple studies. Because of its high purity, resVida[®] has little or no impact on flavour and colour characteristics making it ideal for the inclusion in most food, beverages or dietary supplements. For more information, please visit www.resvida.com.

DSM Press Release

About DSM Nutritional Products

DSM Nutritional Products is the world's leading supplier of vitamins, carotenoids and other fine chemicals to the feed, food, pharmaceutical and personal care industries. The business has sales of over EUR 2 billion and a long tradition as a pioneer in the discovery of new products, new formulations and attractive applications for all industry segments. More information at www.dsmnutritionalproducts.com and www.qualityforlife.com.

DSM – the Life Sciences and Materials Sciences Company

Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM's products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM has annual net sales of EUR 9.3 billion and employs some 23,500 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com.

References

1. Wong R, Berry NM, et al. Acute effects of resveratrol (resVida[®]) supplementation on cardiovascular risk factors. Nutrition Society of Australia and Nutrition Society of New Zealand 2009 Joint Annual Scientific Meeting, Newcastle, NSW, December 8-11, 2009.
2. Berry NM, Wong R, et al. Dose related effects of resveratrol (resVida[®]) on endothelium dependent vasodilatation. International Conference on Polyphenols and Health (ICPH), December 7-10, 2009.
3. Barger JL, T Kayo, et al. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS ONE. 2008; 3(6): e2264.
4. Pearson KJ, JA Baur, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. *Cell Metabolism*. 2008; 8:157-168.
5. Baur JA, KJ Pearson, et al. Resveratrol improves health and survival of mice on a highcalorie diet. *Nature*. 2006; 444: 337-42.
6. Fontana L, Klein S. Aging, Adiposity, and Calorie Restriction. *JAMA*. 2007;297:986-994.

###

For more information:

DSM Nutritional Products
Charlotte Frederiksen
Tel: +41 (0)61 815 83 54
Fax: +41 (0)61 815 88 90
E-mail: charlotte.frederiksen@dsm.com

Forward-looking statements

This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.